COLUMBIA, Md., Feb. 2 Cylex, a leading global life sciences company, announces a revamped corporate image, reflected in its new colors, logo, website (www.cylex.net) and marketing materials. The changes are in keeping with Cylex's dramatic growth over the past five years and recent leadership changes. Cylex is one of the five fastest growing technology, media, telecommunications, life sciences and clean technology companies in the greater Washington D.C. area.
(Logo: http://www.newscom.com/cgi-bin/prnh/20100112/NE34738LOGO )
(Logo: http://www.newscom.com/cgi-bin/prnh/20100202/NE43874LOGO )
"Our new look embodies the essence of the Company and our lead product, ImmuKnow®. In fact, the new modernized image better reflects what Cylex has become today - innovative, strategic and efficient," states CEO and President Brad L. Stewart. In recent years, Cylex has considerably expanded its staff and facility, including new executive appointments last year and continues to expand in Europe and Asia. Cylex recently was awarded a new CPT code for ImmuKnow based on the uniqueness, clinical value and widespread use of the assay.
The product tagline, "Be in the Know," represents the value gained by including ImmuKnow in a patient monitoring strategy. Working from a baseline established for each patient, ImmuKnow is repeated regularly for longitudinal, individualized assessment of changes in global immune function. In other words, assessing global immune function over time puts clinicians in the know. The logo, featuring a light green wave, represents the ability for clinicians to define a range of stable immune function for each of their patients. Combined with individual patients' clinical factors and other routine monitoring tests, ImmuKnow assay results help guide decisions in therapy to avoid over- or under-immunosuppression.
About Cylex, Inc.
Cylex is a privately held global life science company that is the leader in the development and manufacture of in vitro diagnostic products. ImmuKnow is the in vitro diagnostic utilized to detect cell-mediated immunity (CMI) in an immunosuppressed population, and is increasingly being adopted at organ transplant centers throughout the United States and abroad. The Company's patented technology provides an innovative platform allowing clinical researchers to simply and reproducibly measure CMI for the development of new diagnostics, biomarkers and companion assays. The company is based in Columbia, MD USA. For more information, visit www.cylex.net.
ImmuKnow is a noninvasive biomarker of immune function that assesses cellular immune status by detecting cell-mediated immunity (CMI) in adult immunosuppressed patients. It measures the concentration of adenosine triphosphate (ATP) released from CD4 cells following cell stimulation. The ImmuKnow test is a qualitative assay and does not directly quantify the level of immunosuppression. Results of the ImmuKnow assay should be used in conjunction with clinical presentation, medical history, and other clinical indicators when assessing the immune status of any individual patient. For more information, visit www.cylex.net.
SOURCE Cylex, Inc.